Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

This program supports preclinical studies to test existing or investigational drugs, drug combinations, and some combinations with non-drug interventions for Alzheimer’s disease and related dementias. Applicants must be eligible organizations such as nonprofits, universities, governments, businesses, tribal entities, and foreign organizations, and clinical trials are not allowed. NIA plans to spend $6 million in fiscal year 2026 for 4 to 5 awards, with budgets capped at $1 million in direct costs per year and project periods up to 5 years. No cost sharing is required, and foreign organizations and foreign components of U.S. organizations are allowed.

✳ AI-generated summary — verify against the announcement

• Health
• Research & Discovery
• Researchers & Scholars
• Biomedical & Disease Research

• ✓ City or township governments
• ✓ County governments
• ✓ For-profit organizations other than small businesses
• ✓ Independent school districts
• ✓ Native American tribal governments (Federally recognized)
• ✓ Native American tribal organizations (other than Federally recognized)
• ✓ Nonprofits with 501(c)(3) status (other than higher education)
• ✓ Nonprofits without 501(c)(3) status (other than higher education)
• ✓ Others
• ✓ Private institutions of higher education
• ✓ Public and State controlled institutions of higher education
• ✓ Public housing authorities / Indian housing authorities
• ✓ Small businesses
• ✓ Special district governments
• ✓ State governments